The Tobacco Endgame in Asia: Why the World's Largest Cigarette Market Is the Hardest to Change

The China National Tobacco Corporation (CNTC) is not a normal company. It is a state-owned enterprise that produces approximately 40% of the world's cigarettes, employs over 500,000 people, and generates roughly 7-10% of the Chinese government's total tax revenue—an amount that exceeds China's annual defense budget. The CNTC is simultaneously the world's largest cigarette manufacturer, the primary funder of tobacco control research in China (the Chinese Center for Disease Control and Prevention's tobacco control office is housed within the CNTC's administrative structure), and the government agency responsible for implementing the FCTC's provisions on tobacco-product regulation. The conflict of interest is not hidden. It is structural. And it makes tobacco control in China a fundamentally different challenge from tobacco control in any Western country—a challenge that the Western-dominated tobacco control community has never fully understood or effectively addressed.

The scale of the Chinese smoking epidemic is difficult for Western audiences to internalize. Approximately 300 million Chinese adults smoke—roughly the entire population of the United States. Smoking prevalence among Chinese men is approximately 50%, among the highest in the world, while prevalence among Chinese women is approximately 2%, among the lowest (a pattern that reflects cultural norms that historically associated female smoking with promiscuity). The result is an estimated one million tobacco-attributable deaths annually in China—a number projected to rise to two million by 2030 and three million by 2050 if current trends continue. The disease burden is concentrated among men, but the secondhand-smoke burden affects both genders: over 700 million nonsmokers in China are exposed to secondhand smoke daily, and an estimated 100,000 nonsmokers die annually from secondhand-smoke exposure. The scale is staggering. The political response has been inconsistent: China ratified the FCTC in 2005 and has implemented some tobacco control measures (Beijing's smoke-free law, enacted in 2015, is among the strongest in the world on paper but weakly enforced), but the structural dominance of the CNTC over tobacco policy has prevented the comprehensive approach that the FCTC envisions.

The political economy of tobacco in China is the central obstacle. The CNTC's tax contribution, while declining as a share of total government revenue (from approximately 12% in the 1990s to 5-7% in recent years), remains a significant fiscal dependency, particularly for provincial governments in tobacco-growing regions (Yunnan, Guizhou, Henan) where tobacco is a primary economic driver. The CNTC's political influence extends beyond its fiscal contribution: its leadership is appointed by the Communist Party, its interests are represented in every province and municipality through the local tobacco monopoly bureaus, and its narrative—that tobacco control threatens employment, rural livelihoods, and government revenue—carries weight in a political system that prioritizes economic stability and social order. The Western model of tobacco control—independent regulatory agencies, adversarial advocacy, litigation against the industry—is largely inapplicable in a context where the industry is the state, and where challenging the industry means challenging the state.

The harm reduction dimension of the Asian tobacco challenge is particularly complex. Vaping products, largely manufactured in Shenzhen (the global center of vaping hardware production), are widely available in China and across Asia, but the regulatory environment is fragmented and evolving. China's State Tobacco Monopoly Administration—which, notably, is the same agency that oversees the CNTC—has asserted regulatory authority over e-cigarettes, treating them as tobacco products subject to the same monopoly framework that governs cigarettes. The effect has been to bring vaping under the control of the same state-owned entity that dominates the cigarette market—an arrangement that, depending on one's perspective, either creates an opportunity for a managed transition (the CNTC could use its distribution network to promote vaping as an alternative to smoking) or entrenches the conflict of interest (the CNTC has no incentive to cannibalize its cigarette revenue with vaping products, and may use its regulatory authority to restrict vaping in ways that protect the cigarette market). The outcome is uncertain, but the structural dynamics are clear: the entity that controls the cigarette market also controls the regulatory framework for the alternatives. The separation between industry and regulator that is the foundation of Western tobacco control does not exist in China.

The broader Asian picture is diverse and cannot be reduced to the Chinese case. Japan experienced an extraordinarily rapid decline in cigarette consumption following the introduction of heated tobacco products (IQOS and competitors), with cigarette sales falling by over 40% in five years—a decline driven primarily by consumer switching, not by government policy. South Korea, where smoking prevalence among men remains high (approximately 35%), has seen significant growth in vaping and heated tobacco, with the government adopting a harm-reduction-ambivalent regulatory stance that taxes alternative products but does not prohibit them. India, with over 250 million tobacco users (mostly smokeless tobacco and bidis, not manufactured cigarettes), faces a fundamentally different epidemic profile that is poorly addressed by the cigarette-centric model of global tobacco control. Indonesia, with one of the highest male smoking rates in the world (65%), has not ratified the FCTC and has minimal tobacco control infrastructure. The diversity of the Asian tobacco landscape resists the one-size-fits-all approach that characterizes global tobacco control.

The global tobacco control community's engagement with Asia has been inadequate—characterized by a combination of universalistic prescription (apply the FCTC's MPOWER measures, which were designed for Western contexts) and cultural stereotyping (Asians smoke because of cultural norms that are resistant to change). Neither the prescription nor the diagnosis is adequate to the complexity of the Asian tobacco landscape. An effective approach would need to engage with the political economy of state-owned tobacco (in China and several other Asian countries), the cultural embeddedness of specific tobacco practices (the kretek cigarette in Indonesia, the bidi in India, the waterpipe in the Middle East and parts of South Asia), the role of harm reduction in contexts where cessation infrastructure is minimal, and the agency of Asian governments and civil society organizations—which are not passive recipients of Western tobacco control expertise but active participants in shaping their own tobacco futures. The Asian tobacco challenge is the global tobacco challenge—Asia accounts for the majority of the world's smokers and the majority of tobacco-attributable mortality—and the global response has not been commensurate with the scale of the problem.

Shareable insight: China's state-owned tobacco monopoly produces 40% of the world's cigarettes, employs half a million people, and funds the government agencies responsible for tobacco control. The conflict of interest is structural—and it makes the Western model of tobacco control, built on independence from industry, largely inapplicable. The global tobacco epidemic will not be solved without China. China will not solve it without confronting the state-owned monopoly that sustains it.